The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder

Launched by TANTA UNIVERSITY · Dec 28, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called methylphenidate, specifically its brand name Concerta, affects people with borderline personality disorder (BPD). The researchers want to find out if Concerta can help reduce issues like impulsivity (acting quickly without thinking), mood swings, and difficulties with focus in individuals who have BPD. They will also check how safe this medication is for these patients, which is important to see if it could be a helpful option for managing BPD symptoms.

To participate in this study, individuals must be between 18 and 50 years old and have a confirmed diagnosis of borderline personality disorder. They should be experiencing noticeable problems with impulsivity and mood instability. However, people who have other specific conditions, such as ADHD or severe mental health issues, or those who are pregnant or breastfeeding, won't be eligible for this trial. Participants can expect to take Concerta and be monitored for its effects and safety, helping researchers learn more about this medication's role in treating BPD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Individuals aged 18-50 years.
• • Diagnosed with borderline personality disorder as confirmed by a structured clinical interview.
• • Experiencing at least moderate levels of impulsivity and mood instability.
• • Not currently receiving stimulant medication or any pharmacotherapy specifically contraindicated with methylphenidate.
• • Capable of providing informed consent.
• Exclusion Criteria:
• • • Diagnosed with ADHD or other neurodevelopmental disorders where Concerta is typically prescribed.
• • Severe co-morbid psychiatric disorders (e.g., schizophrenia, bipolar disorder) or substance use disorder.
• • Known hypersensitivity to methylphenidate or other stimulant medications.
• • Pregnant or lactating women.
• • Individuals currently undergoing intensive psychotherapy or those unwilling to discontinue existing psychotropic medications that may interact with Concerta.